Percutaneous coronary intervention in patients with diabetes: Current concepts and future directions

Journal of Diabetes Science and Technology

Volumn 8, Issue 3, 2014, Pages 581-589

  Armstrong, Ehrin J ^a   Waltenberger, Johannes ^b   Rogers, Jason H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Coronary artery disease; Diabetes; Drug eluting stents

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; EVEROLIMUS; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; PACLITAXEL; POLYLACTIC ACID; RAPAMYCIN; TICAGRELOR; ZOTAROLIMUS; ANTIDIABETIC AGENT;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; BARE METAL STENT; CONTROLLED DRUG RELEASE; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; DIABETES MELLITUS; DIABETIC PATIENT; DRUG ELUTING STENT; FOLLOW UP; GLYCEMIC CONTROL; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INSULIN TREATMENT; LEFT CORONARY ARTERY; META ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; RESTENOSIS; REVIEW; STABLE ANGINA PECTORIS; STENT THROMBOSIS; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; ADVERSE EFFECTS; COMORBIDITY; DEVICES; FORECASTING; PROSTHESIS DESIGN; RISK FACTOR; TREATMENT OUTCOME; TRENDS;

COMORBIDITY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG-ELUTING STENTS; FORECASTING; HUMANS; HYPOGLYCEMIC AGENTS; PERCUTANEOUS CORONARY INTERVENTION; PROSTHESIS DESIGN; RISK FACTORS; TREATMENT OUTCOME;

EID: 84900812108     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/1932296813517058     Document Type: Review

References (59)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047-1053. (Pubitemid 38579764)
2. Gersh BJ, Sliwa K, Mayosi BM, Yusuf S. The epidemic of cardiovascular disease in the developing world: global implications. Eur Heart J. 2010;31:642-648.
3. Aronson D, Edelman ER. Revascularization for coronary artery disease in diabetes mellitus: angioplasty, stents and coronary artery bypass grafting. Rev Endocr Metab Disord. 2010;11:75-86.
4. Norhammar A, Tenerz A, Nilsson G, et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet. 2002;359:2140-2144. (Pubitemid 34694020)
5. Lankisch M, Futh R, Gulker H, et al. Screening for undiagnosed diabetes in patients with acute myocardial infarction. Clin Res Cardiol. 2008;97:753-759.
6. Shore S, Borgerding JA, Gylys-Colwell I, et al. Association between admission hyperglycemia during hospitalization for acute myocardial infarction and subsequent diabetes: insights from the Veterans Administration Cardiac Care Follow-Up Clinical Study [published online ahead of print October 2, 2013]. Diabetes Care.
7. Creager MA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Circulation. 2003;108:1527-1532. (Pubitemid 37176462)
8. BARI Investigators. The final 10-year follow-up results from the BARI Randomized Trial. J Am Coll Cardiol. 2007;49:1600-1606.
9. Bravata DM, Gienger MAL, McDonald BKM, et al. The comparative effectiveness of percutaneous coronary interventions and coronary artery bypass graft surgery. Ann Intern Med. 2007;147:703-716. (Pubitemid 351664467)
10. BARI 2D Investigators. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360:2503-2515.
11. Dagenais GR, Lu J, Faxon DP, et al. Effects of optimal medical treatment with or without coronary revascularization on angina and subsequent revascularizations in patients with type 2 diabetes mellitus and stable ischemic heart disease. Circulation. 2011;123:1492-1500.
12. Farkouh ME, Domanski M, Sleeper LA, et al. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med. 2012;367:2375-2384.
13. Kamalesh M, Sharp TG, Tang XC, et al. Percutaneous coronary intervention versus coronary bypass surgery in United States veterans with diabetes. J Am Coll Cardiol. 2013;61:808-816.
14. Timmer JR, Ottervanger JP, de Boer M-J, et al. Primary percutaneous coronary intervention compared with fibrinolysis for myocardial infarction in diabetes mellitus: results from the primary coronary angioplasty vs thrombolysis-2 trial. Arch Intern Med. 2007;167:1353-1359. (Pubitemid 47052432)
15. O'Donoghue ML, Vaidya A, Afsal R, et al. An invasive or conservative strategy in patients with diabetes mellitus and non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol. 2012;60:106-111.
16. Stefanini GG, Holmes DR Jr. Drug-eluting coronary-artery stents. N Engl J Med. 2013;368:254-265.
17. Bangalore S, Kumar S, Fusaro M, et al. Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22 844 patient years of follow-up from randomised trials. BMJ. 2012;345:e5170-e5170.
18. Kornowski RR, Mintz GS, Kent KM, et al. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia. A serial intravascular ultrasound study. Circulation. 1997;95:1366-1369. (Pubitemid 27142791)
19. Park SH, Marso SP, Zhou Z, Foroudi F, Topol EJ, Lincoff AM. Neointimal hyperplasia after arterial injury is increased in a rat model of non-insulin-dependent diabetes mellitus. Circulation. 2001;104:815-819. (Pubitemid 32762681)
20. Mosseri M, Nahir M, Rozenman Y, et al. Diffuse narrowing of coronary arteries in diabetic patients: the earliest phase of coronary artery disease. Cardiology. 1998;89:103-110. (Pubitemid 28068600)
21. Armstrong EJ, Feldman DN, Wang TY, et al. Clinical presentation, management, and outcomes of angiographically documented early, late, and very late stent thrombosis. JACC Cardiovasc Interv. 2012;5:131-140.
22. Tanaka N, Terashima M, Rathore S, et al. Different patterns of vascular response between patients with or without diabetes mellitus after drug-eluting stent implantation: optical coherence tomographic analysis. JACC Cardiovasc Interv. 2010;3:1074-1079.
23. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045-1057.
24. Wiviott S, Braunwald E, McCabe C, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001-2015. (Pubitemid 350106708)
25. Stefanini GGG, Kalesan BB, Serruys P, et al. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. Lancet. 2011;378:1940-1948.
26. Kolandaivelu K, Swaminathan R, Gibson W, et al. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation. 2011;123:1400-1409.
27. Hermiller J, Raizner A, Cannon L, et al. Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus-the TAXUS-IV trial. J Am Coll Cardiol. 2005;45:8-8.
28. Mahmud E, Ormiston JA, Turco MA, et al. TAXUS liberté attenuates the risk of restenosis in patients with medically treated diabetes mellitus. JACC Cardiovasc Interv. 2009;2:240-252.
29. Sinning JM, Baumgart D, Werner N, et al. Five-year results of the multicenter randomized controlled open-label study of the CYPHER sirolimus-eluting stent in the treatment of diabetic patients with de novo native coronary artery lesions (SCORPIUS) study: A German multicenter investigation on the effectiveness of sirolimus-eluting stents in diabetic patients. Am Heart J. 2012;163:446-453.e1.
30. Caixeta A, Leon MB, Lansky AJ, et al. 5-year clinical outcomes after sirolimus-eluting stent implantation. J Am Coll Cardiol. 2009;54:894-902.
31. Garg P, Normand S, Silbaugh T, et al. Drug-eluting or bare-metal stenting in patients with diabetes mellitus: results from the Massachusetts Data Analysis Center Registry. Circulation. 2008;118:2277-2285.
32. Bangalore S, Kumar S, Fusaro M, et al. Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22 844 patient years of follow-up from randomised trials. BMJ. 2012;345:e5170-e5170.
33. Otake H, Ako J, Yamasaki M, et al. Comparison of everolimus-versus paclitaxel-eluting stents implanted in patients with diabetes mellitus as evaluated by three-dimensional intravascular ultrasound analysis. Am J Cardiol. 2010;106:492-497.
34. Laynez A, Sardi G, Hauville C, et al. Safety and efficacy of everolimus-eluting stents versus paclitaxel-eluting stents in a diabetic population [published online ahead of print April 23, 2012]. Cathet Cardiovasc Interven.
35. Kim WJ, Lee SW, Park SW, et al. Randomized comparison of everolimus-eluting stent versus sirolimus-eluting stent implantation for de novo coronary artery disease in patients with diabetes mellitus (ESSENCE-DIABETES): results from the ESSENCE-DIABETES trial. Circulation. 2011;124:886-892.
36. Stone GW, Kedhi E, Kereiakes DJ, et al. Differential clinical responses to everolimus-eluting and paclitaxel-eluting coronary stents in patients with and without diabetes mellitus. Circulation. 2011;124:893-900.
37. Kereiakes DJ, Cutlip DE, Applegate RJ, et al. Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system). J Am Coll Cardiol. 2010;56:2084-2089.
38. Kirtane AJ, Patel R, O'Shaughnessy C, et al. Clinical and angiographic outcomes in diabetics from the ENDEAVOR IV trial. JACC Cardiovasc Interv. 2009;2:967-976.
39. Leon MB, Mauri L, Popma JJ, et al. A randomized comparison of the endeavor zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV Trial. J Am Coll Cardiol. 2010;55:543-554.
40. Jain AK, Lotan C, Meredith IT, et al. Twelve-month outcomes in patients with diabetes implanted with a zotarolimus-eluting stent: results from the E-Five Registry. Heart. 2010;96:848-853.
41. Birgelen von CC, Basalus MWZM, Tandjung KK, et al. A randomized controlled trial in second-generation zotarolimus-eluting resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial. J Am Coll Cardiol. 2012;59:1350-1361.
42. Silber S, Serruys PW, Leon MB, et al. Clinical outcome of patients with and without diabetes mellitus after percutaneous coronaryintervention with the resolute zotarolimus-eluting stent. JACC Cardiovasc Interv. 2013;6:357-368.
43. Garg S, Bourantas C, Serruys P. New concepts in the design of drug-eluting coronary stents. Nat Rev Cardiol. 2013;10:248-260.
44. Tanimoto S, Bruining N, van Domburg RT, et al. Late stent recoil of the bioabsorbable everolimus-eluting coronary stent and its relationship with plaque morphology. J Am Coll Cardiol. 2008;52:1616-1620.
45. Diletti R, Serruys P, Farooq V, et al. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design. Am Heart J. 2012;164:654-663.
46. Windecker S, Serruys PW, Wandel S, et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet. 2008;372:1163-1173.
47. Mehilli J, Kastrati A, Wesseley R, et al. Randomized trial of a non-polymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. Circulation. 2006;113:273-279.
48. Brilakis ES, Patel VG, Banerjee S. Medical management after coronary stent implantation. JAMA. 2013;310:189.
49. Farkouh ME, Boden WE, Bittner V, et al. Risk factor control for coronary artery disease secondary prevention in large randomized trials. J Am Coll Cardiol. 2013;61:1607-1615.
50. Holmes DR Jr, Kereiakes DJ, Garg S, et al. Stent thrombosis. J Am Coll Cardiol. 2010;56:1357-1365.
51. Wiviott SD, Braunwald E, Angiolillo DJ, et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38. Circulation. 2008:1626-1636.
52. James S, Angiolillo DJ, Cornel JH, et al. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient outcomes (PLATO) trial. Eur Heart J. 2010;31:3006-3016.
53. DCCT/EDIC Study Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643-2653.
54. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545-2559.
55. Mazeika P, Prasad N, Bui S, Seidelin P. Predictors of angiographic restenosis after coronary intervention in patients with diabetes mellitus. Am Heart J. 2003;145:1013-1021. (Pubitemid 36688252)
56. Lemesle G, Bonello L, de Labriolle A, et al. Prognostic value of hemoglobin A1C levels in patients with diabetes mellitus undergoing percutaneous coronary intervention with stent implantation. Am J Cardiol. 2009;104:41-45.
57. Kooy A, de Jager PJ, Lehert MP, et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med. 2009;169:616-625.
58. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-1589.
59. Habib A, Karmali V, Polavarapu R, et al. Metformin impairs vascular endothelial recovery after stent placement in the setting of locally eluted mammalian target of rapamycin inhibitors via s6 kinase-dependent inhibition of cell proliferation. J Am Coll Cardiol. 2013;61:971-980.